A micrograph showing inflammatory responses in the cortex of the new model mouse. Alzheimer's disease patients and mouse ...

A new study has found important clues about the roles age, sex, hormonal changes and genetics play in how certain biomarkers ...

A new study has found important clues about the roles age, sex, hormonal changes and genetics play in how certain biomarkers ...

Eisai and Biogen can finally put their European regulatory uncertainty surrounding Alzheimer's disease medicine Leqembi ...

Following the nod in the EU, BIIB & Eisai's Leqembi becomes the first therapy to slow the progression of early Alzheimer's ...

Biogen and Eisai’s Alzheimer’s disease (AD) drug Leqembi (lecanemab) has been approved by the European Commission (EC). The ...

Lifeforce, the world's leading longevity medicine program, has introduced the Lifeforce Brain Protection Program, a first-of-its-kind solution for people wanting to proactively take control of their ...

The EU approval comes after Eisai and Biogen were given approval for a new once-monthly intravenous maintenance dose of ...

In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild ...

Individuals with a genetic predisposition to Alzheimer's disease show altered blood levels indicating damaged neuronal contacts as early as 11 years before the expected onset of dementia symptoms.

The first approved drug in the EU to treat patients in the early stages of Alzheimer’s disease has been given the go ahead after more than two years of review. The Alzheimer Society of Ireland (The ...

Individuals with a genetic predisposition to Alzheimer's disease show altered blood levels indicating damaged neuronal contacts as early as 11 years before the expected onset of dementia symptoms.